Bioavailability and biological activity of liquisolid compact formula of repaglinide and its effect on glucose tolerance in rabbits.
El-Houssieny
Boushra M
BM
Department of Biology and Hormonal Evaluation, National Organization for Drug Control and Research (NODCAR), Giza, Egypt;
Wahman
Lobna  F
L
Arafa
Nadia M S
NM
D000284:Administration, Oral; D000818:Animals; D019540:Area Under Curve; D001682:Biological Availability; D001786:Blood Glucose / Q000187:drug effects*; D002219:Carbamates / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D002851:Chromatography, High Pressure Liquid / Q000379:methods; D004304:Dosage Forms; D004339:Drug Compounding; D005951:Glucose Tolerance Test; D006801:Humans; D007004:Hypoglycemic Agents / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D007328:Insulin / Q000097:blood; D008297:Male; D010880:Piperidines / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D011817:Rabbits; D011897:Random Allocation; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity
D001786:Blood Glucose; D002219:Carbamates; D004304:Dosage Forms; D007004:Hypoglycemic Agents; D007328:Insulin; D010880:Piperidines; C072379:repaglinide